Eqis Capital Management Inc. Acquires 4,455 Shares of Uniqure NV (NASDAQ:QURE)

Eqis Capital Management Inc. boosted its holdings in shares of Uniqure NV (NASDAQ:QURE) by 16.4% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 31,581 shares of the biotechnology company’s stock after acquiring an additional 4,455 shares during the quarter. Eqis Capital Management Inc.’s holdings in Uniqure were worth $1,243,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of QURE. OMERS ADMINISTRATION Corp bought a new position in shares of Uniqure in the second quarter valued at approximately $618,000. Carillon Tower Advisers Inc. acquired a new stake in shares of Uniqure in the third quarter worth $12,416,000. Aperio Group LLC acquired a new stake in shares of Uniqure in the second quarter worth $83,000. Botty Investors LLC acquired a new stake in shares of Uniqure in the second quarter worth $78,000. Finally, International Biotechnology Trust PLC acquired a new stake in shares of Uniqure in the second quarter worth $2,147,000. 62.81% of the stock is currently owned by hedge funds and other institutional investors.

In other news, VP Alexander Edward Kuta III sold 4,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $47.26, for a total value of $189,040.00. Following the sale, the vice president now owns 30,578 shares in the company, valued at approximately $1,445,116.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Matthew C. Kapusta sold 8,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $56.48, for a total transaction of $451,840.00. Following the completion of the sale, the chief executive officer now owns 391,230 shares in the company, valued at approximately $22,096,670.40. The disclosure for this sale can be found here. Insiders sold a total of 36,769 shares of company stock worth $1,759,426 in the last 90 days. 2.91% of the stock is owned by corporate insiders.

QURE traded down $0.18 during trading on Wednesday, reaching $53.79. 11,409 shares of the company’s stock were exchanged, compared to its average volume of 584,843. Uniqure NV has a fifty-two week low of $21.98 and a fifty-two week high of $82.49. The company has a quick ratio of 14.33, a current ratio of 14.33 and a debt-to-equity ratio of 0.19. The business has a 50 day moving average price of $45.42 and a 200 day moving average price of $58.07. The company has a market capitalization of $2.34 billion, a P/E ratio of -22.82 and a beta of 0.84.

Uniqure (NASDAQ:QURE) last issued its earnings results on Monday, October 28th. The biotechnology company reported ($0.58) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.23. Uniqure had a negative net margin of 1,670.86% and a negative return on equity of 51.12%. The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.24 million. As a group, research analysts forecast that Uniqure NV will post -3 EPS for the current year.

QURE has been the topic of several research analyst reports. Credit Suisse Group assumed coverage on shares of Uniqure in a research note on Tuesday, November 5th. They issued an “outperform” rating and a $76.00 price objective on the stock. Mizuho assumed coverage on shares of Uniqure in a research note on Thursday, September 12th. They set a “buy” rating and a $67.00 price target on the stock. Chardan Capital reiterated a “buy” rating on shares of Uniqure in a research note on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and set a $73.00 price target on shares of Uniqure in a research note on Monday, October 14th. Finally, BidaskClub upgraded shares of Uniqure from a “hold” rating to a “buy” rating in a research note on Wednesday. One research analyst has rated the stock with a hold rating and seventeen have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $74.53.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.

Featured Article: What is Put Option Volume?

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Uniqure NV (NASDAQ:QURE).

Institutional Ownership by Quarter for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.